Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00236093 · ClinicalTrials.gov registry record · Phase 2
Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain
A Phase 2 study, sponsored by Cephalon.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00236093: Completed Phase 2 study, sponsored by Cephalon.
NCT00236093 is a Phase 2 study that has completed, run by Cephalon. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00236093, a Phase 2 study, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The objective of the study is to monitor the safety (adverse event data) of longer-term use of ACTIQ (Oral Transmucosal Fentanyl Citrate \[OTFC\]) treatment in children with pain associated with cancer, sickle cell disease, or severe burns and breakthrough pain (BTP) who are receiving around the clock (ATC) opioid therapy.
Interventions
- DRUG ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])
Trial Details
| Field | Value |
|---|---|
| Start Date | 2006-10 |
| Phase | Phase 2 |
What the finished NCT00236093 record still lists
NCT00236093 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC]) is the first listed.
NCT00236093 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00236093 about?
NCT00236093 is a clinical study titled "Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain". The objective of the study is to monitor the safety (adverse event data) of longer-term use of ACTIQ (Oral Transmucosal Fentanyl Citrate \[OTFC\]) treatment in children with pain associated with cancer, sickle cell disease, or severe burns and breakthrough pain (BTP) who are receiving around the clo...
What is the current status of trial NCT00236093?
This trial is currently completed. It is a Phase 2 study. The study started on 2006-10.
What interventions are being tested in trial NCT00236093?
The interventions under investigation include: ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC]) (DRUG).
Who is sponsoring clinical trial NCT00236093?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia